GPC1 and familial pancreatic carcinoma: Melo et al. demonstrated that GPC1(+) crExos can be utilized as a potential non-invasive diagnostic and screening marker for the detection of early stages of pancreatic cancer, thereby allowing the possibility of surgical treatment [28].